Name: Recombinant Anti-CD33 x Anti-CD64 Bispecific Antibody (Tandem scFv-Fc)
SKU: BSFVF-115
Rating: 5 (1 reviews)

Recombinant Anti-CD33 x Anti-CD64 Bispecific Antibody (Tandem scFv-Fc) is designed to be expressed as a homodimer, which has 2+2 antigen-binding valency. This format consists of one Fc region and two tandem scFv fragments, in which the anti-CD33/CD64 tandem scFv is fused to the Fc domain. The engineered fragment format is used to extend the half-life. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Acute myeloid leukemia (AML); Ulcerative Colitis (UC); Myelodysplastic syndromes (MDS); Gastric cancer therapy.

Datasheet INQUIRY

Specifications

Targets

CD33 & CD64

Type

Tandem scFv-Fc

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Acute myeloid leukemia (AML); Ulcerative Colitis (UC); Myelodysplastic syndromes (MDS); Gastric cancer

Host Animal 1

Mouse

Host Animal 2

Mouse

Targets

Target 1

CD33

Gene ID

945

UniProt ID

P20138

Alternative Names

CD33; CD33 molecule; Cluster of differentiation 33; p67; SIGLEC3; SIGLEC-3; myeloid cell surface antigen CD33; gp67; CD33 antigen (gp67); sialic acid binding Ig-like lectin 3; sialic acid-binding Ig-like lectin 3

Target 2

CD64

Gene ID

2209

UniProt ID

P12314

Alternative Names

FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD33 x Anti-CD64 Bispecific Antibody (Tandem scFv-Fc) (BSFVF-115). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD33 x Anti-CD64 Bispecific Antibody (Tandem scFv-Fc) (CAT#: BSFVF-115)

Specifications

Targets

Customer Reviews and Q&As